ANKTIVA® with BCG Demonstrates 96% Survival at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only NMIBC December 22, 2025
PADCEV + Keytruda combo Significantly Improves Survival for MIBC Patients Regardless of Cisplatin Eligibility December 22, 2025
Conditional Marketing Authorization Recommendation from EMA Received for ANKTIVA® with BCG for NMIBC Carcinoma in Situ December 15, 2025
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness December 9, 2025
Updated Interim Data from Ph 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients Announced December 9, 2025
MVR-T3011 Latest Clinical Results in BCG-Unresponsive NMIBC Patients Demonstrate High Response December 9, 2025
INLEXZO™ (gemcitabine intravesical system) delivers 74% DFS at one year in BCG-unresponsive, high-risk, papillary-only NMIBC December 9, 2025
FDA Approves KEYTRUDA® and KEYTRUDA QLEX™ (berahyaluronidase alfa-pmph formulation), Each with Padcev®, as Perioperative Treatment for Adults with Cisplatin-Ineligible MIBC November 24, 2025
77.8% Three-Month Complete Response Rate Reported from Ph 3 UTOPIA Trial of UGN-103; FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Received November 10, 2025
Development of UGN-301 (zalifrelimab) to discontinue following completion of Ph 1 dose escalation study November 10, 2025
FDA alignment secured on planned Ph 3 NDV-01 program in 2L BCG-unresponsive NMIBC patients and Intermediate risk NMIBC in the adjuvant setting November 10, 2025
FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX™, Each in Combination with Padcev, for Cisplatin-ineligible Patients with MIBC October 29, 2025
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent LG-IR NMIBC October 7, 2025
PADCEV™ + KEYTRUDA™ combo Significantly Improves Survival before and after SOC (surgical cystectomy) in cisplatin-ineligible MIBC patients September 16, 2025
Robust 24-month CR rate of 41.8% observed for cretostimogene monotherapy in BCG-unresponsive high-risk NMIBC patients September 9, 2025
PADCEV Plus KEYTRUDA Significantly Improves Survival for Cisplatin-ineligible MIBC Patients When Given Before and After Surgery August 19, 2025
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit August 19, 2025